Evidence map›Paper›PMID 28992280›Full record

ArticleNephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association2018

Plasma biomarkers improve prediction of diabetic kidney disease in adults with type 1 diabetes over a 12-year follow-up: CACTI study.

Petter Bjornstad, Laura Pyle, David Z I Cherney, Richard J Johnson, Rachel Sippl, Randy Wong, Marian Rewers, Janet K Snell-Bergeon

Open access · bronzeAbstract read
In one paragraph

Article in Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 25 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Observational
  14. Article
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

Petter BjornstadDepartment of Pediatric Endocrinology, University of Colorado School of Medicine, Aurora, CO, USA.
Laura PyleDepartment of Pediatric Endocrinology, University of Colorado School of Medicine, Aurora, CO, USA.
David Z I CherneyDepartment of Medicine, Division of Nephrology, and Department of Physiology, University of Toronto, ON, Canada.
Richard J JohnsonDepartment of Nephrology, University of Colorado Denver, Aurora, CO, USA.
Rachel SipplBarbara Davis Center for Diabetes, University of Colorado Denver, Aurora, CO, USA.
Randy WongBarbara Davis Center for Diabetes, University of Colorado Denver, Aurora, CO, USA.
Marian RewersDepartment of Pediatric Endocrinology, University of Colorado School of Medicine, Aurora, CO, USA.
Janet K Snell-BergeonDepartment of Pediatric Endocrinology, University of Colorado School of Medicine, Aurora, CO, USA.
University of Colorado Denver · USUniversity of Toronto · CA

Funding

Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
PILOT STUDY--SUBSTRATE METABOLISM IN EXTREMELY LOW BIRTH WEIGHT INFANTSP30DK048520 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI Wendy M Kohrt · 1995 to 2026
$32.6M
UCHSC DIABETES ENDOCRINOLOGY RESEARCH CENTERP30DK057516 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI HUTTON, JOHN C · 2000 to 2010
$14.0M
SUBCLINICAL HEART DISEASE IN INSULIN-DEPENDENT DIABETESR01HL061753 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI REWERS, MARIAN J. · 1999 to 2007
$5.2M
Training Program in Diabetes ResearchT32DK063687 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI Andrea Steck · 2002 to 2026
$5.2M
Complications and Comorbidities of Type 1 DiabetesR01HL113029 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI SNELL-BERGEON, JANET KATHLEEN · 2013 to 2016
$2.9M
Determinants of Accelerated CVD in Type 1 DiabetesR01HL079611 · NHLBI · UNIVERSITY OF COLORADO DENVER · PI REWERS, MARIAN J. · 2004 to 2007
$2.3M
Discovery and validation of biomarkers of cardiovascular complications in type 1 diabetesR01DK116731 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI SNELL-BERGEON, JANET KATHLEEN, ZHANG, QIBIN · 2018 to 2020
$1.1M
NCATS NIH HHS UL1 TR001082NHLBI NIH HHS R01 HL061753NHLBI NIH HHS R01 HL079611NHLBI NIH HHS R01 HL113029NIDDK NIH HHS P30 DK048520NIDDK NIH HHS P30 DK057516NIDDK NIH HHS R01 DK116731NIDDK NIH HHS T32 DK063687
6 · The paper itself

Abstract

Background: The objective of the study was to determine whether plasma biomarkers of kidney injury improve the prediction of diabetic kidney disease (DKD) in adults with type 1 diabetes (T1D) over a period of 12 years. Methods: Participants (n = 527, 53% females) in the Coronary Artery Calcification in T1D (CACTI) Study were examined during 2002-04, at a mean (± standard deviation) age of 39.6 ± 9.0 years with 24.8 years as the median duration of diabetes. Urine albumin-to-creatinine (ACR) and estimated glomerular filtration rate (eGFR) by CKD-EPI (chronic kidney disease epidemiology collaboration) creatinine were measured at the baseline and after mean follow-up of 12.1 ± 1.5 years. Albuminuria was defined as ACR ≥30 mg/g and impaired GFR as eGFR <60 mL/min/1.73 m2. Kidney injury biomarkers (Meso Scale Diagnostics) were measured on stored baseline plasma samples. A principal component analysis (PCA) identified two components: (i) kidney injury molecule-1, calbindin, osteoactivin, trefoil factor 3 and vascular endothelial growth factor; and (ii) β-2 microglobulin, cystatin C, neutrophil gelatinase-associated lipocalin and osteopontin that were used in the multivariable regression analyses. Results: Component 2 of the PCA was associated with increase in log modulus ACR [β ± standard error (SE): 0.16 ± 0.07, P = 0.02] and eGFR (β ± SE: -2.56 ± 0.97, P = 0.009) over a period of 12 years after adjusting for traditional risk factors (age, sex, HbA1c, low-density lipoprotein cholesterol and systolic blood pressure and baseline eGFR/baseline ACR). Only Component 2 of the PCA was associated with incident-impaired GFR (odds ratio 2.08, 95% confidence interval 1.18-3.67, P = 0.01), adjusting for traditional risk factors. The addition of Component 2 to traditional risk factors significantly improved C-statistics and net-reclassification improvement for incident-impaired GFR (ΔAUC: 0.02 ± 0.01, P = 0.049, and 29% non-events correctly reclassified, P < 0.0001). Conclusions: Plasma kidney injury biomarkers can help predict development of DKD in T1D.

Indexed as

AdultBiomarkersDiabetes Mellitus, Type 1Diabetic NephropathiesDisease ProgressionFemaleFollow-Up StudiesGlomerular Filtration RateHumansMaleProspective StudiesRisk FactorsBiomarkers

Identifiers

PMID28992280
PMCPMC6030887
OpenAlexW2746900376

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.